Atai Life Sciences (ATAI) Competitors $1.59 -0.14 (-8.09%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ATAI vs. AVDL, ZYME, SEPN, COGT, BCAX, BCYC, COLL, PAHC, IMTX, and AVBPShould you be buying Atai Life Sciences stock or one of its competitors? The main competitors of Atai Life Sciences include Avadel Pharmaceuticals (AVDL), Zymeworks (ZYME), Septerna (SEPN), Cogent Biosciences (COGT), Bicara Therapeutics (BCAX), Bicycle Therapeutics (BCYC), Collegium Pharmaceutical (COLL), Phibro Animal Health (PAHC), Immatics (IMTX), and ArriVent BioPharma (AVBP). These companies are all part of the "pharmaceutical products" industry. Atai Life Sciences vs. Avadel Pharmaceuticals Zymeworks Septerna Cogent Biosciences Bicara Therapeutics Bicycle Therapeutics Collegium Pharmaceutical Phibro Animal Health Immatics ArriVent BioPharma Avadel Pharmaceuticals (NASDAQ:AVDL) and Atai Life Sciences (NASDAQ:ATAI) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, analyst recommendations, institutional ownership, media sentiment, valuation, earnings, community ranking and profitability. Is AVDL or ATAI more profitable? Atai Life Sciences has a net margin of 0.00% compared to Avadel Pharmaceuticals' net margin of -52.53%. Atai Life Sciences' return on equity of -65.75% beat Avadel Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Avadel Pharmaceuticals-52.53% -93.34% -44.77% Atai Life Sciences N/A -65.75%-52.71% Does the media refer more to AVDL or ATAI? In the previous week, Avadel Pharmaceuticals had 22 more articles in the media than Atai Life Sciences. MarketBeat recorded 31 mentions for Avadel Pharmaceuticals and 9 mentions for Atai Life Sciences. Atai Life Sciences' average media sentiment score of 0.48 beat Avadel Pharmaceuticals' score of -0.03 indicating that Atai Life Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avadel Pharmaceuticals 8 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral Atai Life Sciences 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk & volatility, AVDL or ATAI? Avadel Pharmaceuticals has a beta of 1.47, meaning that its share price is 47% more volatile than the S&P 500. Comparatively, Atai Life Sciences has a beta of 0.78, meaning that its share price is 22% less volatile than the S&P 500. Do analysts recommend AVDL or ATAI? Avadel Pharmaceuticals currently has a consensus price target of $24.43, indicating a potential upside of 127.24%. Atai Life Sciences has a consensus price target of $9.00, indicating a potential upside of 466.04%. Given Atai Life Sciences' higher probable upside, analysts plainly believe Atai Life Sciences is more favorable than Avadel Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avadel Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00Atai Life Sciences 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has better valuation & earnings, AVDL or ATAI? Atai Life Sciences has lower revenue, but higher earnings than Avadel Pharmaceuticals. Avadel Pharmaceuticals is trading at a lower price-to-earnings ratio than Atai Life Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAvadel Pharmaceuticals$27.96M37.01-$160.28M-$0.79-13.61Atai Life Sciences$310K860.65-$40.22M-$0.81-1.96 Do institutionals & insiders have more ownership in AVDL or ATAI? 69.2% of Avadel Pharmaceuticals shares are held by institutional investors. Comparatively, 28.4% of Atai Life Sciences shares are held by institutional investors. 4.8% of Avadel Pharmaceuticals shares are held by insiders. Comparatively, 31.2% of Atai Life Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Does the MarketBeat Community believe in AVDL or ATAI? Avadel Pharmaceuticals received 11 more outperform votes than Atai Life Sciences when rated by MarketBeat users. However, 66.33% of users gave Atai Life Sciences an outperform vote while only 66.02% of users gave Avadel Pharmaceuticals an outperform vote. CompanyUnderperformOutperformAvadel PharmaceuticalsOutperform Votes34266.02% Underperform Votes17633.98% Atai Life SciencesOutperform Votes33166.33% Underperform Votes16833.67% SummaryAtai Life Sciences beats Avadel Pharmaceuticals on 9 of the 17 factors compared between the two stocks. Ad Angel PublishingTesla Execs are Freaking OutIt’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands on it. And Elon Musk has completely restructured Tesla to chase this opportunity. This is a once-in-a-lifetime opportunity that you don’t want to miss.Click here to get the details. Get Atai Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ATAI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATAI vs. The Competition Export to ExcelMetricAtai Life SciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$266.80M$6.48B$5.05B$8.87BDividend YieldN/A8.12%4.97%4.06%P/E Ratio-1.965.5697.3414.18Price / Sales860.65348.141,218.4289.42Price / CashN/A22.1533.5132.79Price / Book1.087.885.805.12Net Income-$40.22M$153.61M$119.07M$225.99M7 Day Performance16.06%-2.00%-1.83%-1.32%1 Month Performance32.50%-7.47%-3.64%0.60%1 Year Performance48.60%31.80%31.62%26.23% Atai Life Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATAIAtai Life Sciences2.3795 of 5 stars$1.59-8.1%$9.00+466.0%+42.0%$266.80M$310,000.00-1.9683Analyst ForecastAVDLAvadel Pharmaceuticals2.3424 of 5 stars$10.75+0.3%$24.43+127.2%-7.5%$1.03B$27.96M0.00154Short Interest ↓ZYMEZymeworks2.4008 of 5 stars$14.55-1.5%$19.00+30.6%+74.0%$1.02B$76.01M0.00290SEPNSepternaN/A$22.50-7.0%$43.67+94.1%N/A$1.02BN/A0.00N/AAnalyst ForecastNews CoverageGap UpCOGTCogent Biosciences2.866 of 5 stars$9.08+0.2%$14.83+63.4%+20.6%$1.00BN/A0.0080Analyst RevisionBCAXBicara Therapeutics3.1692 of 5 stars$18.38-4.9%$43.33+135.8%N/A$1.00BN/A0.0032Analyst RevisionBCYCBicycle Therapeutics2.8475 of 5 stars$20.36-0.6%$40.13+97.1%+49.4%$968.12M$26.98M-6.19240Analyst RevisionCOLLCollegium Pharmaceutical3.9744 of 5 stars$30.00+0.8%$42.60+42.0%+17.2%$967.50M$566.77M12.93210PAHCPhibro Animal Health4.2227 of 5 stars$23.39-1.5%$16.50-29.5%+123.4%$961.95M$1.02B54.401,940Analyst DowngradeIMTXImmatics2.0118 of 5 stars$7.80-0.1%$16.67+113.7%-9.2%$930.98M$70.87M-8.76260Analyst ForecastNews CoverageAVBPArriVent BioPharma1.0036 of 5 stars$27.410.0%$36.80+34.3%N/A$923.64MN/A0.0040 Related Companies and Tools Related Companies AVDL Competitors ZYME Competitors SEPN Competitors COGT Competitors BCAX Competitors BCYC Competitors COLL Competitors PAHC Competitors IMTX Competitors AVBP Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ATAI) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atai Life Sciences Please log in to your account or sign up in order to add this asset to your watchlist. Share Atai Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
